Poseida.jpg
Poseida Therapeutics, Inc. Announces Worldwide License Agreement With Janssen to Apply Centyrin Technology in the Development of Chimeric Antigen Receptor (CAR) Therapies
11 août 2015 06h00 HE | Poseida Therapeutics, Inc.
SAN DIEGO, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Poseida Therapeutics, Inc. (Poseida), a private biotechnology company spun out of Transposagen Biopharmaceuticals, Inc. (Transposagen), and headquartered...
Kura Oncology Logo
Kura Oncology to Present at the 2015 Wedbush PacGrow Healthcare Conference
05 août 2015 07h30 HE | Kura Oncology, Inc.
LA JOLLA, Calif., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and...
TetraLogic Announces Update on MDS Clinical Program
30 juin 2015 16h01 HE | TetraLogic Pharmaceuticals
MALVERN, Pa., June 30, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
Global Next-generation Antibody Therapeutics Market Will Reach US$ 6,761.1 Million by 2022: Persistence Market Research
29 juin 2015 04h12 HE | Persistence Market Research
New York, June 29, 2015 (GLOBE NEWSWIRE) -- According to a new market report published by Persistence Market Research "Global Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody...
NeuPharma Announces the Initiation of Phase I Clinical Trial of Novel Na+/K+-ATPase Inhibitor RX108 in Cancer Patients
08 juin 2015 03h00 HE | NeuPharma
SUZHOU, China, June 08, 2015 (GLOBE NEWSWIRE) -- Suzhou NeuPharma Co., Ltd. today announced that it has initiated the first-in-human Phase I clinical trial of RX108 in Australia.  RX108 is a...
Kura Oncology to Present at the Jefferies 2015 Global Healthcare Conference
27 mai 2015 07h30 HE | Kura Oncology, Inc.
LA JOLLA, Calif., May 27, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and...
Behind the Scenes of Breast Cancer, Researchers Collect Genetic Clues in BRCA Database
07 mai 2015 20h38 HE | ARUP Laboratories
SALT LAKE CITY, May 7, 2015 (GLOBE NEWSWIRE) -- As thousands turn out this spring to run and walk in memory of loved ones lost to breast cancer, behind-the-scene researchers are running a race of a...
Cortice Biosciences Announces Updated Results From a Phase 1/2 Clinical Trial Evaluating TPI 287 for Treatment of Recurrent Glioblastoma
21 avr. 2015 09h26 HE | Cortice Biosciences
  – 56% objective response rate in 16 evaluable patients treated with TPI 287 plus Avastin® –  – Overall survival results maturing: median 12.6 months; 73% alive at 9 months, 67% alive at...
Cortice Biosciences Announces Upcoming Clinical Trial Presentation at the 15th Annual Meeting of the American Association for Cancer Research
09 avr. 2015 10h39 HE | Cortice Biosciences
NEW YORK, April 9, 2015 (GLOBE NEWSWIRE) -- Cortice Biosciences announced today that updated results from CB-017, a multi-center Phase 1/2 trial evaluating TPI 287 plus bevacizumab (Avastin®) for the...
AIMLogo.jpg
Hemispherx's Ampligen(R) Provides Anti-Tumor Activity Analogous to Emerging Immune Checkpoint Inhibitors
16 déc. 2014 08h30 HE | AIM ImmunoTech Inc.
PHILADELPHIA, Dec. 16, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today further progress on developing Ampligen® (rintatolimod)...